FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220717070> ?p ?o ?g. }

• W4220717070 endingPage "572" @default.
• W4220717070 startingPage "565" @default.
• W4220717070 abstract "Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for treating patients with locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). In this review, we discuss recent developments in the optimization of RR-DTC treatment with lenvatinib.Initiation of lenvatinib treatment before a worsening of Eastern Cooperative Oncology Group performance status and elevated neutrophil-to-lymphocyte ratio could benefit patients with progressive RR-DTC. The median duration of response with lenvatinib was inversely correlated with a smaller tumor burden, and prognosis was significantly worse in patients with a high tumor burden. An 18 mg/day starting dose of lenvatinib was not noninferior to 24 mg/day and had a comparable safety profile. Timely management of adverse events is crucial, as patients with shorter dose interruptions benefitted more from lenvatinib treatment. Caution should be exercised when initiating lenvatinib in patients who have tumor infiltration into the trachea or other organs, or certain histological subtypes of DTC, as these are risk factors for fistula formation or organ perforation. The Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT) eligibility criteria should be considered prior to initiating lenvatinib treatment.Current evidence indicates that patients benefit most from lenvatinib treatment that is initiated earlier in advanced disease when the disease burden is low. A starting dose of lenvatinib 24 mg/day, with dose modifications as required, yields better outcomes as compared to 18 mg/day. Appropriate supportive care, including timely identification of adverse events, is essential to manage toxicities associated with lenvatinib, avoid longer dose interruptions, and maximize efficacy." @default.
• W4220717070 created "2022-04-03" @default.
• W4220717070 creator A5007551001 @default.
• W4220717070 creator A5011675274 @default.
• W4220717070 creator A5026698479 @default.
• W4220717070 creator A5032324073 @default.
• W4220717070 creator A5038765255 @default.
• W4220717070 creator A5042123586 @default.
• W4220717070 creator A5051214374 @default.
• W4220717070 creator A5055086811 @default.
• W4220717070 creator A5071060296 @default.
• W4220717070 creator A5081409867 @default.
• W4220717070 date "2022-04-28" @default.
• W4220717070 modified "2023-09-30" @default.
• W4220717070 title "Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit" @default.
• W4220717070 cites W1893157045 @default.
• W4220717070 cites W1967792499 @default.
• W4220717070 cites W1982906652 @default.
• W4220717070 cites W1993750017 @default.
• W4220717070 cites W2025066188 @default.
• W4220717070 cites W2107863647 @default.
• W4220717070 cites W2145150141 @default.
• W4220717070 cites W2168076926 @default.
• W4220717070 cites W2172179325 @default.
• W4220717070 cites W2182110379 @default.
• W4220717070 cites W2211781899 @default.
• W4220717070 cites W2291457300 @default.
• W4220717070 cites W2341073448 @default.
• W4220717070 cites W2468271403 @default.
• W4220717070 cites W2613793516 @default.
• W4220717070 cites W2626124580 @default.
• W4220717070 cites W2730479427 @default.
• W4220717070 cites W2735359179 @default.
• W4220717070 cites W2763508020 @default.
• W4220717070 cites W2766510145 @default.
• W4220717070 cites W2768523107 @default.
• W4220717070 cites W2802371751 @default.
• W4220717070 cites W2893012274 @default.
• W4220717070 cites W2901321106 @default.
• W4220717070 cites W2901553335 @default.
• W4220717070 cites W2901821482 @default.
• W4220717070 cites W2905726151 @default.
• W4220717070 cites W2942405584 @default.
• W4220717070 cites W2973282481 @default.
• W4220717070 cites W2975387808 @default.
• W4220717070 cites W2976988657 @default.
• W4220717070 cites W2995149618 @default.
• W4220717070 cites W2996441645 @default.
• W4220717070 cites W2999800942 @default.
• W4220717070 cites W3006662655 @default.
• W4220717070 cites W3015996980 @default.
• W4220717070 cites W3023942810 @default.
• W4220717070 cites W3047622054 @default.
• W4220717070 cites W3111548073 @default.
• W4220717070 cites W3130911259 @default.
• W4220717070 cites W3131063362 @default.
• W4220717070 cites W3131928172 @default.
• W4220717070 cites W3161172313 @default.
• W4220717070 cites W3201658013 @default.
• W4220717070 cites W3205433234 @default.
• W4220717070 cites W4226407945 @default.
• W4220717070 doi "https://doi.org/10.1093/oncolo/oyac065" @default.
• W4220717070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35482606" @default.
• W4220717070 hasPublicationYear "2022" @default.
• W4220717070 type Work @default.
• W4220717070 citedByCount "6" @default.
• W4220717070 countsByYear W42207170702022 @default.
• W4220717070 countsByYear W42207170702023 @default.
• W4220717070 crossrefType "journal-article" @default.
• W4220717070 hasAuthorship W4220717070A5007551001 @default.
• W4220717070 hasAuthorship W4220717070A5011675274 @default.
• W4220717070 hasAuthorship W4220717070A5026698479 @default.
• W4220717070 hasAuthorship W4220717070A5032324073 @default.
• W4220717070 hasAuthorship W4220717070A5038765255 @default.
• W4220717070 hasAuthorship W4220717070A5042123586 @default.
• W4220717070 hasAuthorship W4220717070A5051214374 @default.
• W4220717070 hasAuthorship W4220717070A5055086811 @default.
• W4220717070 hasAuthorship W4220717070A5071060296 @default.
• W4220717070 hasAuthorship W4220717070A5081409867 @default.
• W4220717070 hasBestOaLocation W42207170701 @default.
• W4220717070 hasConcept C121332964 @default.
• W4220717070 hasConcept C121608353 @default.
• W4220717070 hasConcept C126322002 @default.
• W4220717070 hasConcept C142424586 @default.
• W4220717070 hasConcept C143998085 @default.
• W4220717070 hasConcept C197934379 @default.
• W4220717070 hasConcept C2776264508 @default.
• W4220717070 hasConcept C2779761222 @default.
• W4220717070 hasConcept C71924100 @default.
• W4220717070 hasConcept C87355193 @default.
• W4220717070 hasConceptScore W4220717070C121332964 @default.
• W4220717070 hasConceptScore W4220717070C121608353 @default.
• W4220717070 hasConceptScore W4220717070C126322002 @default.
• W4220717070 hasConceptScore W4220717070C142424586 @default.
• W4220717070 hasConceptScore W4220717070C143998085 @default.
• W4220717070 hasConceptScore W4220717070C197934379 @default.
• W4220717070 hasConceptScore W4220717070C2776264508 @default.
• W4220717070 hasConceptScore W4220717070C2779761222 @default.

• next